Skip to content
AnalystLens

Neurocrine Biosciences Annual Report, Year Ended Dec 31, 2024

Filing Date
Filed February 10, 2025
Period End
December 31, 2024
Security
NBIX
One revenue dollarkept$0.14
In the record · 2016–202610-K1210-Q338-K128

NBIX filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 128 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’19Jan ’19
  2. Leadership change8-K · May ’22May ’22
  3. Leadership change8-K · Sep ’26Sep ’26

Summary

Summary of the 10-K filed February 10, 2025. Cited figures are marked; the original filing is the authoritative source.

Neurocrine Biosciences, Inc. reported net product sales of $2.33 billiona for 2024, up from $1.86 billion in 2023, driven primarily by INGREZZA, which generated $2.31 billion in net product sales and accounted for substantially all product sales.

Total revenues were $2.36 billionb, operating income was $570.5 million, and net income was $341.3 million, compared with $249.7 million in 2023. Diluted EPS was $3.29. Results were partly offset by $138.4 million of charges associated with the conversion and settlement of the 2024 convertible senior notes and by higher research and development expense of $731.1 million, up from $565.0 million.

The company launched CRENESSITY for classic congenital adrenal hyperplasia in December 2024 following FDA approval, and it expanded its pipeline. Osavampator advanced into Phase 3 for major depressive disorder after the company converted its Takeda profit-share arrangement into a royalty-bearing license in January 2025. NBI-1117568 completed Phase 2 in schizophrenia and is expected to enter Phase 3 in the first half of 2025.

Cash, cash equivalents and marketable securities totaled $1.82 billionc at year-end, and working capital was $1.22 billion. Investors should note the concentration of revenue: four customers represented approximately 93% of total product sales in 2024.

The filing also highlights exposure to Medicare drug price negotiation under the Inflation Reduction Act, although INGREZZA qualified for the small biotech exception and the specified small manufacturer discount phase-in. The company completed a $300.0 milliond accelerated share repurchase in February 2025, and its CEO transitioned from Kevin Gorman to Kyle Gano in October 2024.

Key Highlights

  1. Net product sales rose to $2,330.6 million in 2024 from $1,860.6 million in 2023, with INGREZZA contributing $2,313.5 million.
  2. Net income increased to $341.3 million from $249.7 million; diluted EPS was $3.29 versus $2.47 in 2023.
  3. Operating income was $570.5 million, compared with $250.9 million in 2023.
  4. Research and development expense increased to $731.1 million from $565.0 million, including $71.7 million in milestone costs.
  5. CRENESSITY launched in December 2024 as the first-in-class FDA-approved treatment for classic CAH.
  6. Four customers accounted for approximately 93% of total product sales in 2024, a concentration risk.
  7. Cash, cash equivalents and marketable securities totaled $1,815.6 million at December 31, 2024; the company completed a $300.0 million accelerated share repurchase in February 2025.

Follow one dollar

Of each $1.00 of revenue in FY2024, Neurocrine Biosciences kept $0.14.

  1. Revenue$2.36B100.0%
  2. Cost of revenue−$34.0M1.4%
  3. Gross profit$2.32B98.6%
  4. Operating costs−$1.75B74.3%
  5. Operating income$570.5M24.2%
  6. Interest, other & tax−$229.2M9.7%
  7. Net income$341.3M14.5%
Computed from 10-KFY2024filed February 10, 2025Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Where FY2024 revenue went

$2.36B
  • SG&A: $1.01B, 43% of revenue
  • Other operating costs: $743.6M, 32% of revenue
  • Net income: $341.3M, 14% of revenue
  • Cost of revenue: $34.0M, 1.4% of revenue
  • Interest, other & tax: $229.2M, 9.7% of revenue

Kept 14% as net incomeCost of revenue $34.0M · 1.4%

Full revenue history →

Financial Statements

FY2024 against FY2023

Line itemFY2024FY2023Change
Revenue$2.36B$1.89B+24.8%
Cost of Revenue$34.00M$39.70M−14.4%
Gross Profit$2.32B$1.85B+25.7%
SG&A Expenses$1.01B$887.60M+13.5%
Operating Expenses$1.78B$1.64B+9.1%
Operating Income$570.50M$250.90M+127.4%
Net Income$341.30M$249.70M+36.7%
EPS (Basic)$3.40$2.56+32.8%
EPS (Diluted)$3.29$2.47+33.2%
Shares Outstanding (Basic)100.40M97.70M+2.8%
Shares Outstanding (Diluted)103.70M101.00M+2.7%

Frequently Asked Questions

  1. What drove the increase in revenue in 2024?

    The filing attributes the increase in net product sales primarily to INGREZZA, which was driven by strong underlying patient demand and improved gross-to-net dynamics. INGREZZA net product sales were $2,313.5 million in 2024 compared with $1,836.0 million in 2023.

  2. What were the main sources of earnings pressure in 2024?

    Total other expense, net was $84.5 million, including $138.4 million of charges associated with the 2024 convertible senior notes and a $37.1 million unrealized loss on equity investments. Research and development spending rose to $731.1 million, and selling, general and administrative expense increased to $1,007.2 million.

  3. What is the status of the company's pipeline and recent licensing changes?

    Osavampator entered Phase 3 development for major depressive disorder in January 2025, after the Takeda profit-share arrangement was converted to a royalty-bearing license. NBI-1117568 completed Phase 2 in schizophrenia and is expected to advance to Phase 3 in the first half of 2025. The company also terminated the luvadaxistat license with Takeda, effective in April 2025.

  4. What are the key risks related to pricing and reimbursement?

    INGREZZA is reimbursed under Medicare Part D. The Inflation Reduction Act's Part D manufacturer discount program may affect INGREZZA revenues, and the company is still evaluating the impact of its designation as a specified small manufacturer. INGREZZA qualified for the small biotech exception from Medicare price negotiation until 2027, and the filing notes that AUSTEDO, a competing product, was selected for negotiation in 2025.

  5. How concentrated is the company's customer base?

    The filing states that four customers represented approximately 93% of total product sales for 2024 and approximately 98% of accounts receivable as of December 31, 2024. Loss of any significant customer could adversely affect revenue, results of operations and cash flows.